374 related articles for article (PubMed ID: 29996069)
1. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
4. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody utilization characteristics in patients with multiple myeloma.
Ailawadhi S; Sher T; Azzouqa AG; Meghji Z; Jain T; Jani P; Ahmed S; Diehl N; Roy V; Shah V; Hodge D; Ailawadhi M; Alegria VR; Paulus A; Chanan-Khan A; Fonseca R
Anticancer Drugs; 2019 Sep; 30(8):859-865. PubMed ID: 31415286
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
Nishimura N; Terui Y; Hatake K
Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
9. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
Hofmeister CC; Lonial S
J Clin Oncol; 2016 Dec; 34(36):4421-4430. PubMed ID: 27998219
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
11. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
13. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
[TBL] [Abstract][Full Text] [Related]
14. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD
Cancer; 2018 Nov; 124(22):4358-4365. PubMed ID: 30303526
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
16. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
[TBL] [Abstract][Full Text] [Related]
17. Safety of ninety-minute daratumumab infusion.
Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
19. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
20. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN
Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]